FindTrial
Sign In

The application of Iris fluorescein angiography in the conbercept treatement of proliferative diabetic retinopathy

The application of Iris fluorescein angiography in the conbercept treatement of proliferative diabetic retinopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017279
Enrollment
Unknown
Registered
2018-07-20
Start date
2018-07-20
Completion date
Unknown
Last updated
2018-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

proliferative diabetic retinopathy

Interventions

control:vitrectomy
Trial 1:intravitreal injection of conbercept combined with vitrectomy therapy according to iris fluorescein angiography
Trial 2:intravitreal injection of conbercept combined with vitrectomy therapy

Sponsors

Tianjin Medical University Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.proliferative diabetic retinopathy patients

Exclusion criteria

Exclusion criteria: 1. patients had any treatment or surgery for ocular disease; 2. patients had any other systematic disease except diabetes; 3. patients had any other ocular disease except proliferative diabetic retinopathy.

Design outcomes

Primary

MeasureTime frame
fundus new vessels;iris new vessels;—

Countries

China

Contacts

Public ContactZhang Longli

Tianjin Medical University Eye Hospital

zhanglonglieye@126.com+86 18622856317

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026